Skip to main content

Advertisement

SpringerLink
Log in

Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The aim of this study was to evaluate the feasibility of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy followed by concurrent weekly cisplatin chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Methods

Between 2010 and 2013, 30 patients with Stage IV HNSCC were treated in Hokkaido University Hospital with three cycles of induction chemotherapy (docetaxel 75 mg/m2 and cisplatin 75 mg/m2, day 1; and 5-fluorouracil 750 mg/m2/day 120 h continuous infusion, every 3 weeks) followed by concurrent weekly cisplatin (40 mg/m2, on weeks 1, 2, 3, 5, 6 and 7) chemoradiotherapy.

Results

Three courses of induction chemotherapy were performed in 25 patients (83 %) with grade 3–4 toxicities during induction chemotherapy observed in 22 patients (73 %). The major toxicities were hematologic, with 22 cases (73 %) showing grade 3–4 neutropenia. Radiotherapy was completed (70 Gy) in 29 patients (97 %), while a total of 19 patients (63 %) completed five (13 patients) or six (6 patients) courses of chemotherapy. During concurrent chemoradiotherapy, no grade 4 hematological toxicities were observed. Grade 4 dermatitis was observed in one patient, and grade 3 mucositis was observed in 12 patients. There were no treatment-related deaths during the induction chemotherapy or concurrent chemoradiotherapy. The 1- and 2-year progression-free survival rates and the 1- and 2-year overall survival rates were 86 %, 72 %, and 89 %, 81 %, respectively.

Conclusion

Sequential therapy composed of induction chemotherapy followed by concurrent weekly cisplatin chemoradiotherapy is feasible, showing encouraging results in patients with locally advanced HNSCC. Concurrent weekly cisplatin chemoradiotherapy following induction chemotherapy appears to be a suitable alternative to three-weekly high-dose cisplatin therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pignon JP, le Maitre A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14

    Article  PubMed  Google Scholar 

  2. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098

    Article  CAS  PubMed  Google Scholar 

  3. Adelstein DJ (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98

    Article  PubMed  Google Scholar 

  4. Traynor AM, Richards GM, Hartig GK et al (2009) Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. Head Neck 32:599–606

    Google Scholar 

  5. Newlin HE, Amdur RJ, Riggs CE et al (2010) Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 116:4533–4540

    Article  PubMed  Google Scholar 

  6. Sharma A, Mohanti BK, Thakar A et al (2010) Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial. Ann Oncol 21:2272–2277

    Article  CAS  PubMed  Google Scholar 

  7. Homma A, Inamura N, Oridate N et al (2011) Concomitant weekly cisplatin and radiotherapy for head and neck cancer. Jpn J Clin Oncol 41:980–986

    Article  PubMed  Google Scholar 

  8. Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715

    Article  CAS  PubMed  Google Scholar 

  9. Haddad R, O’Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14:257–264

    Article  CAS  PubMed  Google Scholar 

  10. Vermorken JB, Remenar E, van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704

    Article  CAS  PubMed  Google Scholar 

  11. Paccagnella A, Ghi MG, Loreggian L et al (2010) Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 21:1515–1522

    Article  CAS  PubMed  Google Scholar 

  12. Lefebvre JL, Pointreau Y, Rolland F et al (2013) Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN Randomized Phase II Study. J Clin Oncol 31:853–859

    Article  CAS  PubMed  Google Scholar 

  13. Mizumachi T, Kano S, Sakashita T et al (2013) Improved survival of Japanese patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. Int J Clin Oncol 18:824–828

    Article  PubMed  Google Scholar 

  14. Adelstein DJ, Moon J, Hanna E et al (2009) Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: a Southwest Oncology Group phase II trial (S0216). Head Neck 32:221–228

    Google Scholar 

  15. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al (2005) Phase III Study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636–8645

    Article  PubMed  Google Scholar 

  16. Pointreau Y, Garaud P, Chapet S et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. JNCI 101:498–506

    Article  CAS  PubMed  Google Scholar 

  17. Prestwich RJ, Oksuz DC, Dyker K et al (2011) Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 81:e237–e243

    Article  CAS  PubMed  Google Scholar 

  18. Zenda S, Matsuura K, Tachibana H et al (2011) Multicenter phase II study of an opioid-based pain control program for head and neck cancer patients receiving chemoradiotherapy. Radiother Oncol 101:410–414

    Article  CAS  PubMed  Google Scholar 

  19. Zenda S, Onozawa Y, Tahara M et al (2007) Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results. Jpn J Clin Oncol 37:725–729

    Article  PubMed  Google Scholar 

  20. Rutter CE, Yovino S, Taylor R et al (2011) Impact of early percutaneous endoscopic gastrostomy tube placement on nutritional status and hospitalization in patients with head and neck cancer receiving definitive chemoradiation therapy. Head Neck 33:1441–1447

    Article  PubMed  Google Scholar 

  21. Spector ME, Gallagher KK, Light E et al (2012) Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head Neck 34:1727–1733

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Conflict of interest

No author has any conflict of interest.

Author information

Authors and Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, 060-8638, Japan

    Takatsugu Mizumachi, Akihiro Homma, Tomohiko Kakizaki, Tomohiro Sakashita, Satoshi Kano, Hiromitsu Hatakeyama & Satoshi Fukuda

  2. Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    Kazuhiko Tsuchiya, Koichi Yasuda, Rikiya Onimaru & Hiroki Shirato

  3. Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    Jun Taguchi, Yasushi Shimizu, Ichiro Kinoshita & Hirotoshi Akita

Authors
  1. Takatsugu Mizumachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akihiro Homma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomohiko Kakizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomohiro Sakashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoshi Kano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiromitsu Hatakeyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuhiko Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Koichi Yasuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rikiya Onimaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroki Shirato
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jun Taguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yasushi Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ichiro Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hirotoshi Akita
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Satoshi Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takatsugu Mizumachi.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mizumachi, T., Homma, A., Kakizaki, T. et al. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. Int J Clin Oncol 20, 431–437 (2015). https://doi.org/10.1007/s10147-014-0726-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-014-0726-y

Keywords

Search

Navigation